BR112021013180A2 - Composição farmacêutica, vetor viral não replicante, e, método para prover terapia celular adotiva - Google Patents
Composição farmacêutica, vetor viral não replicante, e, método para prover terapia celular adotivaInfo
- Publication number
- BR112021013180A2 BR112021013180A2 BR112021013180A BR112021013180A BR112021013180A2 BR 112021013180 A2 BR112021013180 A2 BR 112021013180A2 BR 112021013180 A BR112021013180 A BR 112021013180A BR 112021013180 A BR112021013180 A BR 112021013180A BR 112021013180 A2 BR112021013180 A2 BR 112021013180A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell therapy
- adoptive cell
- pharmaceutical composition
- viral vector
- replicating viral
- Prior art date
Links
- 238000011467 adoptive cell therapy Methods 0.000 title abstract 3
- 230000003362 replicative effect Effects 0.000 title abstract 3
- 239000013603 viral vector Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
Abstract
composição farmacêutica, vetor viral não replicante, e, método para prover terapia celular adotiva. a descrição provê vetores virais não replicantes (rnv) para terapia celular adotiva. os rnvs podem entregar receptores de antígenos quiméricos às células imunes (por exemplo, células t) in vivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962788894P | 2019-01-06 | 2019-01-06 | |
PCT/US2020/012417 WO2020142780A1 (en) | 2019-01-06 | 2020-01-06 | Car t cell methods and constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021013180A2 true BR112021013180A2 (pt) | 2022-04-12 |
Family
ID=71406633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021013180A BR112021013180A2 (pt) | 2019-01-06 | 2020-01-06 | Composição farmacêutica, vetor viral não replicante, e, método para prover terapia celular adotiva |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220090132A1 (pt) |
EP (1) | EP3906311A4 (pt) |
JP (1) | JP2022516710A (pt) |
KR (1) | KR20210137427A (pt) |
CN (1) | CN113382741A (pt) |
AU (1) | AU2020205000A1 (pt) |
BR (1) | BR112021013180A2 (pt) |
CA (1) | CA3125201A1 (pt) |
IL (1) | IL284461A (pt) |
SG (1) | SG11202107246TA (pt) |
WO (1) | WO2020142780A1 (pt) |
ZA (1) | ZA202103899B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117567650B (zh) * | 2024-01-15 | 2024-04-02 | 中国人民解放军东部战区总医院 | 共表达细胞间黏附分子icam2的car-t细胞及其制备方法与应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
DK3214091T3 (en) * | 2010-12-09 | 2019-01-07 | Univ Pennsylvania | USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER |
JP6894236B2 (ja) * | 2014-03-26 | 2021-06-30 | デノボ バイオファーマ エルエルシー | 免疫刺激活性を有するレトロウイルスベクター |
MA46236A (fr) * | 2016-09-14 | 2019-07-24 | Janssen Biotech Inc | Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes |
CA3068634A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
-
2020
- 2020-01-06 CN CN202080007932.2A patent/CN113382741A/zh active Pending
- 2020-01-06 KR KR1020217020488A patent/KR20210137427A/ko unknown
- 2020-01-06 WO PCT/US2020/012417 patent/WO2020142780A1/en active Application Filing
- 2020-01-06 JP JP2021537208A patent/JP2022516710A/ja active Pending
- 2020-01-06 SG SG11202107246TA patent/SG11202107246TA/en unknown
- 2020-01-06 EP EP20736060.3A patent/EP3906311A4/en active Pending
- 2020-01-06 US US17/419,239 patent/US20220090132A1/en active Pending
- 2020-01-06 BR BR112021013180A patent/BR112021013180A2/pt unknown
- 2020-01-06 CA CA3125201A patent/CA3125201A1/en active Pending
- 2020-01-06 AU AU2020205000A patent/AU2020205000A1/en not_active Abandoned
-
2021
- 2021-06-07 ZA ZA2021/03899A patent/ZA202103899B/en unknown
- 2021-06-29 IL IL284461A patent/IL284461A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210137427A (ko) | 2021-11-17 |
WO2020142780A1 (en) | 2020-07-09 |
CA3125201A1 (en) | 2020-07-09 |
SG11202107246TA (en) | 2021-07-29 |
US20220090132A1 (en) | 2022-03-24 |
ZA202103899B (en) | 2022-09-28 |
EP3906311A4 (en) | 2022-09-28 |
IL284461A (en) | 2021-08-31 |
JP2022516710A (ja) | 2022-03-02 |
AU2020205000A1 (en) | 2021-06-17 |
EP3906311A1 (en) | 2021-11-10 |
CN113382741A (zh) | 2021-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010241A (es) | Composiciones de inmunoterapia celular y usos de las mismas. | |
WO2020092854A3 (en) | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) | |
MX2019013312A (es) | Composiciones para facilitar la fusion de membranas y usos de estas. | |
MX2020012927A (es) | Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular. | |
MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
PH12018501453A1 (en) | Chimeric proteins and methods of immuno therapy | |
MX2018001568A (es) | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. | |
PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
PE20180695A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de prostata y otros tipos de cancer | |
BR112019007100A2 (pt) | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão | |
MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
PE20180174A1 (es) | Nuevos epitopos celulares y nuevas combinaciones de epitopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cancer | |
PE20190477A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
MX2021008143A (es) | Metodos para cosechar cultivos de celulas de mamifero. | |
BR112021021843A2 (pt) | Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas | |
BR112018003535A2 (pt) | receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão | |
WO2018102787A9 (en) | Methods for determining car-t cells dosing | |
AR116048A1 (es) | Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión | |
WO2019242632A8 (en) | Engineered cells and uses thereof | |
BR112021017365A2 (pt) | Receptores de citocina quiméricos constitutivamente ativos | |
NI201600127A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA. | |
CO2022004603A2 (es) | Inmunoterapia con anticuerpos biespecíficos de células car | |
EP3765070A4 (en) | SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES |